GSK plc announced on May 21, 2024, that its asthma medication depemokimab showed positive phase III trial results with significant reductions in asthma attacks over 52 weeks compared to placebo, indicating potential for six-month dosing. This event is significant for the company as it may lead to a new treatment option for millions suffering from severe asthma.